Efficacy and safety of gefitinib and potential prognostic value of soluble EGFR, EGFR mutations, and tumor markers in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer

被引：0
|
作者：
Leslie, K. K. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Sill, M. W. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Darcy, K. M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Baron, A. T. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Wilken, J. A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Godwin, A. K. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Cook, L. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Schilder, R. J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Schilder, J. M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Maihle, N. J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构：
[1] Univ New Mexico, Albuquerque, NM 87131 USA
[2] Univ Iowa, Albuquerque, NM USA
[3] Gynecol Oncol Grp, Stat Off, Buffalo, NY USA
[4] Univ Kentucky, Lexington, KY USA
[5] Yale Univ, New Haven, CT USA
[6] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[7] Indiana Univ, Bloomington, IN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16542
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies
    Usha, Lydia
    Sill, Michael W.
    Darcy, Kathleen M.
    Benbrook, Doris M.
    Hurteau, Jean A.
    Michelin, David P.
    Mannel, Robert S.
    Hanjani, Parviz
    De Geest, Koen
    Godwin, Andrew K.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (03) : 455 - 461
  • [22] ECHINOMYCIN IN RECURRENT AND METASTATIC ENDOMETRIAL CARCINOMA - A PHASE-II TRIAL OF THE GYNECOLOGIC-ONCOLOGY-GROUP
    MUSS, HB
    BLESSING, JA
    DUBESHTER, B
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1993, 16 (06): : 492 - 493
  • [23] A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: A study by the Gynecologic Oncology Group
    Garcia, Agustin A.
    Blessing, John A.
    Nolte, Susan
    Mannel, Robert S.
    GYNECOLOGIC ONCOLOGY, 2008, 111 (01) : 22 - 26
  • [24] Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study
    Alberts, David S.
    Blessing, John A.
    Landrum, Lisa M.
    Warshal, David P.
    Martin, Lainie P.
    Rose, Stephen L.
    Bonebrake, Albert J.
    Ramondetta, Lois M.
    GYNECOLOGIC ONCOLOGY, 2012, 127 (03) : 451 - 455
  • [25] A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): A gynecologic oncology group study
    Sabbatini, Paul
    Sill, Michael W.
    O'Malley, David
    Adler, Lisa
    Secord, Angeles Alvarez
    GYNECOLOGIC ONCOLOGY, 2008, 111 (03) : 455 - 460
  • [26] A PHASE-II TRIAL OF VINCRISTINE IN ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
    BROUN, GO
    BLESSING, JA
    EDDY, GL
    ADELSON, MD
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1993, 16 (01): : 18 - 21
  • [27] Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas - A Gynecologic Oncology Group study
    Miller, DS
    Blessing, JA
    Kilgore, LC
    Mannel, R
    Van Le, L
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (04): : 355 - 357
  • [28] A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study (vol 127, pg 538, 2012)
    Coleman, Robert L.
    Sill, Michael W.
    Lankes, Heather A.
    Fader, Amanda Nickles
    Finkler, Neil J.
    Hoffman, James S.
    Rose, Peter G.
    Sutton, Gregory P.
    Drescher, Charles W.
    McMeekin, D. Scott
    Hu, Wei
    Deavers, Michael
    Godwin, Andrew K.
    Alpaugh, R. Katherine
    Sood, Anil K.
    GYNECOLOGIC ONCOLOGY, 2013, 130 (01) : 252 - 253
  • [29] Phase II study of the efficacy of gefitinib in patients with non-small cell lung cancer with the EGFR mutations.
    Sunaga, N.
    Yanagitani, N.
    Kaira, K.
    Tomizawa, Y.
    Iijima, H.
    Otani, Y.
    Tanaka, S.
    Suga, T.
    Dobashi, K.
    Mori, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 409S - 409S
  • [30] Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group
    Russell J. Schilder
    John A. Blessing
    Michael L. Pearl
    Peter G. Rose
    Investigational New Drugs, 2004, 22 : 343 - 349
12345